 Home > Biochemistry News > Biotechnology News > The application for phase III clinical trial of HER2 double antibody KN026 was officially accepted by CDE

The application for phase III clinical trial of HER2 double antibody KN026 was officially accepted by CDE

 Last Update: 2021-11-16
 Source: Internet
 Author: User

Tags

food product packaging

fda accession number

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Suzhou, October 21, 2021/PRNewswire/ - Corning Jereh Biopharmaceuticals (stock code: 9966.

Gastric cancer and gastroesophageal junction adenocarcinoma (GC/GEJ) is the fifth most common malignant tumor in the world and the third leading cause of tumor death

The data of the Phase II study released at the ASCO Annual Meeting in 2021 showed that KN026 has a good effect in patients with advanced HER2-positive gastric and gastroesophageal junction cancer, regardless of whether the patient has received trastuzumab therapy in the past

This IND application is the second registered clinical study carried out by KN026 after KN026 combined with KN046 for the treatment of HER2-positive solid tumors, and it is also the first phase III clinical study of KN026

About KN026

KN026 is an anti-HER2 bispecific antibody developed by Corning Jereh using Fc heterodimer platform technology (CRIB) with independent intellectual property rights.

KN026 has been approved by the National Medical Products Administration (NMPA) and the U.

In August 2021, Corning Jerry and Shanghai Jinmante Biotechnology Co.

About Corning Jerry

Corning Jereh Biopharmaceuticals focuses on the research and development, production and commercialization of innovative anti-tumor drugs

Corning Jereh Biopharmaceuticals has a discovery, R&D, and manufacturing platform for the entire industry chain in bispecific antibody and protein engineering

The company has a number of technical platforms with independent intellectual property rights such as heterodimers and hybrid antibodies, and large-scale production capabilities that meet the cGMP standards of China, the United States and the European Union, and have passed a complete quality system including multiple audits of the European Union QP.

About CSPC

CSPC is a national-level innovative enterprise with strong capabilities in the development, production and marketing of innovative drugs

Source: Corning Jerry

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.